近年来我国生物技术药物研究进展和趋势  

The Research Progress and Trend of Biotech Drugs in Recent Years in China

作　　者：王友同[1] 吴文俊[1] 李谦[1,2] 高美风[1,2] 

机构地区：[1]中国药科大学药物生物技术编辑部,江苏南京210009 [2]中国药科大学生命科学与技术学院,江苏南京210009

出　　处：《药物生物技术》2013年第1期1-11,共11页Pharmaceutical Biotechnology

摘　　要：生物技术是21世纪世界各国竞相发展的经济、技术的制高点,作者站在世界生物技术药物发展总趋势的高度上,具体而微地调查和总结了我国近5年来生物技术药物研究所取得的成果,内容包括:细胞因子、其它蛋白质和多肽药物、融合蛋白、穿膜肽、酶、基因治疗、干细胞、单克隆抗体、治疗性疫苗及多糖药物等。调查发现,在攻克人类顽疾、保障人民身体健康、提高生活质量和发展我国生物技术药物产业方面,由于国内成批有创见的研究成果持续涌现,发展前景一片光明。该文可为有关部门科研规划、确定研究项目、企业锁定发展目标及生物制药人员选择专业发展方向提供参考。Biological technology is the topic height at the development of economy and technology in the 21st century all over theworld . The authors based on the world biotech- drugs total development trend, summarized the biotech drugs research achievements in recent five years in China. The content includes ： cytokine, protein and peptide drugs, fusion protein, cell-penetrating peptides, enzymes, gene therapy, stem cells, monoclonal antibodies, therapeutic vaccine, polysaccharide drugs, etc. It is found in the survey that the development of biotech drugs has a bright future in treating complicated diseases, protecting the human health, improving the life quality, and developing the biotech drugs industry, thank to the emerging of many creative biotech drug researches within our country. This paper provides the reference for establishing the relevant research plan, deciding the research project, setting development goals for enterprise research, and choosing professional development direction, and to biological pharmaceutical researchers.

关 键 词：生物技术药物 细胞因子 融合蛋白 酶 单克隆抗体 基因治疗 干细胞 

分 类 号：Q811.4[生物学—生物工程]